CN1070226C - 五倍子油脂及其提取方法和制药用途 - Google Patents
五倍子油脂及其提取方法和制药用途 Download PDFInfo
- Publication number
- CN1070226C CN1070226C CN98111966A CN98111966A CN1070226C CN 1070226 C CN1070226 C CN 1070226C CN 98111966 A CN98111966 A CN 98111966A CN 98111966 A CN98111966 A CN 98111966A CN 1070226 C CN1070226 C CN 1070226C
- Authority
- CN
- China
- Prior art keywords
- gallnut
- oil
- acid
- grease
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 27
- 239000004519 grease Substances 0.000 claims abstract description 19
- 230000007935 neutral effect Effects 0.000 claims abstract description 15
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 9
- 238000005325 percolation Methods 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims description 90
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 9
- 235000019197 fats Nutrition 0.000 claims description 8
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 238000007127 saponification reaction Methods 0.000 claims description 7
- 239000007901 soft capsule Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 238000007803 cold maceration Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 3
- 239000010685 fatty oil Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004232 linoleic acid Drugs 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229960002969 oleic acid Drugs 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 229960004274 stearic acid Drugs 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- 229940032091 stigmasterol Drugs 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 239000007962 solid dispersion Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000011084 recovery Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000013456 study Methods 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- -1 β-Gu Zaichun Chemical class 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WVAKABMNNSMCDK-UHFFFAOYSA-N sulfacarbamide Chemical compound NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 WVAKABMNNSMCDK-UHFFFAOYSA-N 0.000 description 1
- 229950010053 sulfacarbamide Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 例数(只) | 血 糖 | 降糖率 | |||||
造模后3天 | 7天 | 给药3h | 3天 | 5天 | 3天 | 5天 | ||
模型组 | 5 | 247.0±36.2 | 285.5±38.6 | 260.3±32.8 | 276.2±35.5 | 264.3±37.1 | - | - |
五倍子油脂 | 5 | 243.6±34.7 | 290.5±42.5 | 284.1±42.9 | 150.6±33.0 | 95.5±26.9 | 45.47 | 63.8 |
组 别 | 例数(只) | 造模2h血糖(mg/dl) | 给药一周后 | ||
血糖(mg/dl) | 降糖率(%) | ||||
模型组 | 10 | 245.06±2.75 | 263.74±41.53 | - | |
五倍子油脂 | (纯化前) | 10 | 239.80±44.72 | 141.02±31.64 | 46.53 |
(纯化后) | 10 | 227.58±76.24 | 160.12±39.35 | 39.29 |
组别 | 例数(只) | 剂量×次数(mg/jk×c) | 给药后血糖值(mg/dl) | ||
0.5h | 1.0h | 2h | |||
模型组 | 10 | 等容积N.S×3 | 396.8±82.5 | 285.0±58.3 | 193.7±42.6 |
五倍子油脂 | 10 | 40×3 | 311.1±68.5 | 213.2±42.4 | 166.7±46.1 |
组别 | 例数(只) | 剂量×次数(mg/jk×c) | 给药后血糖值(mg/dl) | |||
0h | 0.5h | 1.0h | 2h | |||
模型组 | 6 | 等容积N.S×3 | 308.3±74.6 | 246.7±62.4 | 167.4±38.1 | 105.5±23.5 |
五倍子油脂 | 6 | 40×3 | 289.4±66.4 | 220.8±56.2 | 126.7±34.8 | 73.8±18.4 |
组别 | 例数 | 显效(%) | 有效(%) | 无效(%) | 有效率% |
治疗组 | 30 | 11(36.7) | 15(50.0) | 4(13.3) | 86.7 |
对照组 | 30 | 20(66.7) | 10(33.4) | 0 | 100.0 |
组别 | N | 治疗前 | 治疗后 | 差值 | P值 |
治疗组 | 30 | 11.5±1.03 | 9.17±0.64 | 2.45±0.41 | <0.01 |
对照组 | 30 | 10.92±1.36 | 8.20±0.55 | 2.85±0.33 | <0.01 |
组别 | N | 治疗前 | 治疗后 | 差值 | P值 |
治疗组 | 30 | 14.7±0.56 | 11.5±0.82 | 3.16±0.41 | <0.01 |
对照组 | 30 | 14.54±1.06 | 10.01±1.16 | 4.48±1.15 | <0.01 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98111966A CN1070226C (zh) | 1998-04-21 | 1998-04-21 | 五倍子油脂及其提取方法和制药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98111966A CN1070226C (zh) | 1998-04-21 | 1998-04-21 | 五倍子油脂及其提取方法和制药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1232866A CN1232866A (zh) | 1999-10-27 |
CN1070226C true CN1070226C (zh) | 2001-08-29 |
Family
ID=5221850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98111966A Expired - Lifetime CN1070226C (zh) | 1998-04-21 | 1998-04-21 | 五倍子油脂及其提取方法和制药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1070226C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102002433A (zh) * | 2010-12-08 | 2011-04-06 | 张家界奥威科技有限公司 | 一种五倍子角倍油脂组合物及其制备方法 |
CN102080017A (zh) * | 2010-12-08 | 2011-06-01 | 张家界奥威科技有限公司 | 一种五倍子肚倍油组合物及其制备方法 |
CN102002434A (zh) * | 2010-12-08 | 2011-04-06 | 张家界奥威科技有限公司 | 一种五倍子倍花油组合物及其制备方法 |
CN102488714B (zh) * | 2011-12-15 | 2013-04-17 | 张家界奥威科技有限公司 | 一种五倍子倍蚜油组合物、制备方法及其用途 |
CN102703207A (zh) * | 2012-07-06 | 2012-10-03 | 栾川县野生源生态科技开发有限公司 | 一种山茱萸核油的提取方法 |
CN103690567B (zh) * | 2012-12-28 | 2016-04-27 | 中国医学科学院药用植物研究所 | 一种五倍子的乙酸乙酯提取物检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156607A (zh) * | 1996-12-17 | 1997-08-13 | 马洪钧 | 双五降糖胶囊 |
-
1998
- 1998-04-21 CN CN98111966A patent/CN1070226C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156607A (zh) * | 1996-12-17 | 1997-08-13 | 马洪钧 | 双五降糖胶囊 |
Non-Patent Citations (1)
Title |
---|
湖南中医学院学报1990年10卷4期 1990.1.1 李文海临床用药心得录 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080362A (ja) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
JP4719372B2 (ja) * | 2000-06-21 | 2011-07-06 | 花王株式会社 | Ppar依存的遺伝子転写活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1232866A (zh) | 1999-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1283258C (zh) | 一种抗肝纤维化的药物及其制备方法 | |
CN103169788B (zh) | 大枣叶提取物及其在制备防治肝损伤药物及保健食品中的应用 | |
CN1070226C (zh) | 五倍子油脂及其提取方法和制药用途 | |
CN101926865B (zh) | 酸枣仁解郁安神组合物及其制备方法 | |
CN1749262A (zh) | 亚麻籽木脂素总糖苷提取物的制备方法及其应用 | |
CN1850069A (zh) | 藤茶素分散片的制备方法及用途 | |
CN1733054A (zh) | 一种山茱萸提取物及其制备工艺 | |
CN1215071C (zh) | 飞蓬酯乙及其制备方法和在制药中的应用 | |
CN1733031A (zh) | 脑得生口服液及其制备方法 | |
CN1742829A (zh) | 一种治疗冠心病心绞痛的滴丸剂及其制备方法 | |
CN1264533C (zh) | 一种复方丹参胶囊及制备方法 | |
CN1067258C (zh) | 猕猴桃根及其有效部位的用途 | |
CN1560061A (zh) | 怀山药提取物怀山药皂甙的提取方法 | |
CN1194741C (zh) | 一种灯盏细辛复方药剂 | |
CN1857706A (zh) | 一点红总黄酮及其药物组合物生产方法 | |
CN1272054C (zh) | 治疗糖尿病的药物及其制备方法 | |
CN1839869A (zh) | 莫罗苷在α-葡萄糖苷酶抑制剂中的应用 | |
CN1686434A (zh) | 复方蛤青滴丸及其制备方法 | |
CN1843460A (zh) | 降糖降脂降压、改善微循环及免疫的药剂及其制备方法 | |
CN1475222A (zh) | 匙羹藤叶精提物及其制备工艺 | |
CN1679831A (zh) | 一种治疗心脑血管疾病的口服药物及其制法 | |
CN1583009A (zh) | 一种抗哮喘的中药提取物和制剂及制备方法 | |
CN1118278C (zh) | 乌索酸在制备治疗病毒性肝炎药物中的应用 | |
CN1647800A (zh) | 一种河鲀油制剂及其制备方法 | |
CN1201742C (zh) | 一种用于ⅱ型糖尿病的降血糖保健食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO Free format text: FORMER OWNER: LI SUQIONG; HUANG QINGFU; YANG KUI Effective date: 20060331 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060331 Address after: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: Chengdu Kanghong Sci-Tech Industry (Group) Co., Ltd. Address before: 610061, 25 locust tree street, Sichuan, Chengdu Co-patentee before: Huang Qingfu Patentee before: Li Suqiong Co-patentee before: Yang Kui |
|
ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO Free format text: FORMER OWNER: LI SUQIONG; PU XUFENG; YANG KUI Effective date: 20060526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060526 Address after: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: Chengdu Kanghong Sci-Tech Industry (Group) Co., Ltd. Address before: 610061, 25 locust tree street, Sichuan, Chengdu Co-patentee before: Pu Xufeng Patentee before: Li Suqiong Co-patentee before: Yang Kui |
|
ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG MEDICINE GROUP CO.LTD. Free format text: FORMER OWNER: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. Effective date: 20080926 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080926 Address after: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: Chengdu Kanghong Pharmaceuticals Group Co., Ltd. Address before: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: Chengdu Kanghong Sci-Tech Industry (Group) Co., Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20010829 |
|
CX01 | Expiry of patent term |